{"disease":{"id":"absence-seizure","name":"Absence seizure","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"valproate","indication_name":"Simple and Complex Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valproate","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its anti-epileptic effects."},{"drug_id":"valproate","indication_name":"Multiple Seizure Types Including Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valproate","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its anti-epileptic effects."},{"drug_id":"clonazepam","indication_name":"Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"valproate-sodium","indication_name":"Simple and Complex Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALPROATE SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its antiepileptic effects."},{"drug_id":"valproate-sodium","indication_name":"Multiple Seizure Types Including Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALPROATE SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its antiepileptic effects."},{"drug_id":"sodium valproate","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"zarontin","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zarontin","generic_name":"Ethosuximide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-dependent T-type calcium channel subunit alpha-1G","drug_class":"Succinimide","quality_score":10,"revenue":null,"mechanism":"Suppresses paroxysmal three cycle per second spike and wave activity associated with absence seizures."},{"drug_id":"lorazepam","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ativan","generic_name":"lorazepam","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clonazepam","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethadione","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Didione","generic_name":"ethadione","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"ethadione","quality_score":null,"revenue":null,"mechanism":"Didione works by modulating the activity of neurons in the brain to control seizures."},{"drug_id":"valproic-acid","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"acetazolamide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"phensuximide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Succitimal","generic_name":"PHENSUXIMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-gated T-type calcium channel","drug_class":"phensuximide","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"paramethadione","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paradione","generic_name":"PARAMETHADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-gated T-type calcium channel","drug_class":"paramethadione","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethosuximide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zarontin","generic_name":"ETHOSUXIMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-dependent T-type calcium channel subunit alpha-1G","drug_class":"Anti-epileptic Agent [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"methsuximide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celontin","generic_name":"METHSUXIMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-gated T-type calcium channel","drug_class":"Anti-epileptic Agent","quality_score":0,"revenue":null,"mechanism":"Celontin works by blocking the activity of voltage-gated T-type calcium channels in the brain."},{"drug_id":"mesuximide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"mesuximide","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_2","molecular_target":"Voltage-gated T-type calcium channel","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"divalproex","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"klonopin","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Klonopin","company_name":"Par Pharmaceutical, Inc.","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04439656","title":"Detecting Absence Seizures Using Eye Tracking","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Rachel Kuperman","has_results":false},{"nct_id":"NCT04615442","title":"ECV - Epihunter Clinical Validation","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Epihunter NV","has_results":false},{"nct_id":"NCT06093490","title":"Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT06310772","title":"Assessing Comorbidities in Epilepsy Using Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT04899050","title":"Epidiolex in Typical Absence Seizures","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"University of South Florida","has_results":false}],"total":5},"guidelines":[{"drug_id":"zarontin","guideline_body":"FDA label","recommendation":"Zarontin is indicated for the control of absence (petit mal) epilepsy.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"valproic-acid","guideline_body":"FDA label","recommendation":"Valproic acid oral solution is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures.","line_of_therapy":"1L|adj","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}